Evidence map›Paper›PMID 34201500›Full record

ArticleBiomedicines2021

Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric

Mark Kerstjens, Patricia Garrido Castro, Sandra S Pinhanços, Pauline Schneider, Priscilla Wander, Rob Pieters, Ronald W Stam

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Updates inBiomedicines · 2023
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mark KerstjensPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Patricia Garrido CastroPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Sandra S PinhançosPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.ORCID 0000-0002-6748-5554
Pauline SchneiderPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.ORCID 0000-0003-0162-9436
Priscilla WanderPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Rob PietersPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Ronald W StamPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Princess Máxima Center · NL

Funding

Stichting Kinderen Kankervrij 277
6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) in infants (<1 year of age) remains one of the most aggressive types of childhood hematologic malignancy. The majority (~80%) of infant ALL cases are characterized by chromosomal translocations involving the

Indexed as

irinotecanMLL translocationpediatric acute leukemiaxenograft mouse models

Identifiers

PMID34201500
PMCPMC8301450
OpenAlexW3173180201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.